NCT05136404View on ClinicalTrials.gov

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Healthy
Interventions
DRUG

Selpercatinib

Administered orally

Trial Locations (1)

32117

LabCorp CRU, Inc., Daytona Beach

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Loxo Oncology, Inc.

INDUSTRY